Author Archives: Bruno Quinney

MRI showing glioblastoma
#Brain cancer #Clinical trial #PhoreMost

PhoreMost advances brain cancer programme to trial  

PhoreMost has announced a treatment for brain cancers as its lead programme, also appointing Dr Gabriel Fox as Chief Medical Officer.  The biotechnology company will progress PMC-001, a next-generation, small molecule microtubule targeting agent (MTA) for primary and secondary brain cancers, towards Phase I clinical trial.  PMC-001 is… Read More

#Cancer Research #News

Histology slides
#Endometriosis #Women's health

Oriva appoints Arbat as CEO, advances endometriosis asset 

Women’s health company Oriva Therapeutics has appointed Dr Agnès Arbat as Chief Executive Officer.  Arbat joins with more than 25 years of experience in the pharmaceutical industry, which Oriva says demonstrate a strong track record across clinical development, medical affairs and commercial strategy in women’s health.  Arbat… Read More

#News

#Cancer research #Clinical trial #Drug discovery #Funding #Genetic profiling #GLP-1 #Lung cancer #MHRA #National Institute for Health and Care Research #Obesity #Oncology #Rare disease #Regulatory #The Francis Crick Institute #The Royal Marsden NHS Foundation Trust #University College London #Weight loss

This week in Drug Discovery (8 – 12 June) 

News round-up for 8 – 12 June by Bruno Quinney, Content Team at DDW.  This week, new research suggests anti-IL-1β drugs could prevent lung cancer. Elsewhere, the UK is set to benefit from specialised blood tests and funding for researchers.   The top stories:   … Read More

#News

Cell and gene therapies
#Cell and gene therapy #Macrophages #Solid tumours #T-Cells

Laverock reports positive data from oncology programmes 

Laverock Therapeutics has reported in vivo functional milestones across its T-cell and macrophage oncology programmes as it advances its lead programme towards clinic.  Data from ovarian cancer models, presented at the American Society of Cell and Gene Therapy (ASCGT) Annual Meeting in May, demonstrated the company’s… Read More

#Cancer Research #News

GSK offices
#Biopharma #GSK #Non-small cell lung cancer (NSCLC)

GSK acquires Nuvalent and cancer therapy pipeline 

GSK has reached an agreement to acquire biopharmaceutical company Nuvalent for $10.6 billion.  The agreement includes GSK’s purchase of three therapies for lung cancer, including Zidesamtinib (NVL-250) and neladalkib (NVL-655). The candidates are late-stage, potential best-in-class, next-generation, highly selective ROS1 and ALK inhibitors for treatment of non-small cell lung cancer (NSCLC). … Read More

#Business & Investment #News #Trending News

#GLP-1 #Obesity #Weight loss

Obesity therapies could offer benefits beyond weight loss 

MetaVia has presented data showing its obesity therapies could offer broader benefits than weight loss alone.  DA-1726, a novel dual agonist targeting glucagon-like peptide-1 receptors (GLP1R) and glucagon receptors (GCGR), reduced body weight by 9.1% at Day 54 in a Phase I trial, as well as reducing waist… Read More

#News

#Antibiotics #Clinical trial

Fungus-derived compounds could treat aggressive cancer 

Researchers have identified chemical compounds derived from a fungus that could help treat an aggressive cancer, the Journal of Antibiotics reports.  The compounds, named paramyfurans A and B and paramylactone, were extracted from a fungal strain called Paramyrothecium sp. BF-1049. They were tested against three mesothelioma cell lines in a laboratory setting, with… Read More

#Cancer Research #Editor's Choice #News

#AI #Drug discovery #Sygnature Discovery

DaltonTx launches AI drug discovery platform 

DaltonTx has launched an AI drug discovery platform which could help scientists “make better-informed decisions earlier in the discovery process”.  The platform, called Dalton, seeks to integrate agentic AI, human expertise and experimental data into a continuous learning engine.   DaltonTx says the platform links molecules, assays, models, experimental outcomes, project context and human decisions… Read More

#News

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Drug discovery #Investment #Life sciences #Oncology

Bead BioPharma emerges from stealth with novel drug platform 

Bead BioPharma has emerged from stealth by submitting a patent for a novel cancer drug platform.  The life sciences company, backed by Archangels, submitted the patent in efforts to launch its formal entry into one of the most competitive sectors of global oncology.  Bead BioPharma is focused on antibody-drug conjugates (ADCs), a class of cancer therapies sometimes… Read More

#Business & Investment #News

Vaccine
#Covid-19 #Immunology / Virology & Vaccines #University of Cambridge

‘Universal’ vaccine could protect from several viruses at once 

A novel ‘universal’ vaccine has been engineered to provide protection from thousands of variants in one single dose.  Results from a first-in-human clinical trial, published in the Journal of Infection, show the vaccine protected participants from multiple Sarbeco coronaviruses, a large group of viruses including SARS-CoV-2, as… Read More

#News

Bacteria in Petri dishes
#Antimicrobial resistance (AMR) #United States

AMR Bio confirms contribution to US National Action Plan 

Biotechnology company AMR Bio has submitted written comments in efforts to shape the US National Action Plan to combat antibiotic-resistant bacteria.  AMR Bio wrote to the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB) ahead of the council’s 27th public meeting on 16 June 2026, contributing to the next iteration… Read More

#News

#Boehringer Ingelheim #GLP-1 #Obesity #Weight loss

GLP-1 reduces liver fat by 63%, trial results show 

The glucagon/GLP-1 dual agonist survodutide could reduce liver fat by 63%, results show.  Boehringer Ingelheim reported positive results from two Phase III trials, which demonstrated patients lost 63% liver fat, 34% visceral fat and showed minimal lean mass change at the highest dose.  The results demonstrate survodutide’s potential to… Read More

#News

Multiple myeloma
#Myeloma #National Institute for Health and Care Excellence (NICE) #UK

NICE recommends quadruplet regimen for multiple myeloma 

The UK’s National Institute for Health and Care Excellence (NICE) has recommended Darzalex (daratumumab) as a combination therapy for untreated multiple myeloma.  NICE recommended the therapy, developed by Johnson & Johnson, with bortezomib, lenalidomide and dexamethasone (D-VRd) for untreated multiple myeloma in adults when an autologous stem cell transplant (ASCT) is unsuitable.  The recommendation is… Read More

#News #Regulatory

Scientist looking through microscope
#Cancer research #Clinical trial #Genetic profiling #The Royal Marsden NHS Foundation Trust #UK

UK cancer patients to benefit from genetic testing rollout 

Hundreds of UK cancer patients will benefit from a rollout of specialised blood tests, providing improved access to genetic testing and personalised therapies.  The Royal Marsden, who are partnering with Guardant Health, will provide circulating tumour DNA (ctDNA) molecular profiling, using the Guardant360 Liquid assay powered by Infinity.   These… Read More

#News

Chronic gout
#Clinical trial #Crystalys Therapeutics #Gout

Crystalys doses first patients in Phase II gout trial 

Crystalys Therapeutics has dosed the first patients in a Phase II trial evaluating a treatment for difficult-to-treat gout.  The trial will evaluate dotinurad, a next-generation, once daily, oral URAT1 inhibitor with the potential to deliver best-in-class safety and efficacy for the treatment of gout, particularly in patients with limited treatment… Read More

#News

#AI #Cancer research #Cervical cancer #Clinical trial #Colorectal cancer #Genetics / genomics #Head and neck cancer #MHRA #Obesity #Pistoia Alliance #Precision medicine #University College London #University of Cambridge #Weight loss

DDW Highlights: 9 June 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a cancer drug demonstrated it could reduce tumours by as much as… Read More

#Podcasts